Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.
View the full Corporate Spotlight
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 17.0¢ | Day High | 17.0¢ | Day Low | 17.0¢ | |||
| Daily Volume | 12950 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 2 | 16.5¢ | 80606 | 4 | 17.0¢ | 35980 | |
| Dr. Michael Thurn | Chief Executive Officer, Managing Director, Director |
| Mr. Dan O'connell | Chief Financial Officer |
| Mr. John Clark | Chief Operating Officer |
| Dr. Nicky Wallis | Chief Scientific Officer |
| Ms. Fiona Milner | General Manager - Epichem Pty Ltd |
| Ms. Kathryn Williams | Chief Regulatory Officer |
| Mr. Stefan Ross | Company Secretary |
| Mr. Sergio Duchini | Non-Executive Chairman of the Board |
| Mr. Marcus Paul Hughes | Non-Executive Director |
| Dr. Kathryn Macfarlane | Non-Executive Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.010(6.25%) |
Mkt cap ! $78.76M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 17.0¢ | $2.202K | 12.95K |
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 80606 | 16.5¢ |
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 35980 | 4 |
| Last trade - 10.19am 31/07/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |
